

# CURRICULUM VITAE

**Leslie Hendeles, Pharm.D.**

April 2009

---

## BIOGRAPHICAL

**Home Address:** 3549 N.W. 30th Blvd. **Home Phone/Fax:** 352-377-0954

Gainesville, FL 32605

**Business Address:** University of Florida **Business Phone:** 352-273-6027  
Health Science Center (Box 100486)  
1600 SW Archer Road, Room PG-05 **Business Fax:** 352-273-6120  
Gainesville, FL 32610-0486

**Email Address:** hendeles@cop.ufl.edu **Cell Phone:** 352-494-7932

## EDUCATION

Pharm.D., University of Southern California,  
Los Angeles, CA , June 1969

Undergraduate Psychology, San Francisco State College,  
San Francisco, CA, 1964-1965

Pre-Pharmacy, Los Angeles City College,  
Los Angeles, CA, 1961-1963

## LICENSES/CERTIFICATES

Registered Pharmacist, Florida, 1981-present  
National Provider Identifier # 1205944584

Asthma Educator, National Asthma Educator Certification Board, 2003

Spirometry Certificate, National Institute for Occupational Safety and  
Health, 2000

Asthma Disease State Management Examination, National Association of  
Boards of Pharmacy, passed 1999

## AWARDS AND HONORS

Pediatric Pharmacy Advocacy Group, Sumner J. Yaffe Lifetime  
Achievement Award for 2007

University of Florida Research Foundation Professorship Award for 2003-  
2006, March 2003

University of Florida Working Professional Pharm.D. Program, Outstanding  
Faculty of the Year, August 2002

American Pharmaceutical Association, Research Achievement Award in Pharmaceutical Sciences, March 2002

American College of Clinical Pharmacy, Therapeutic Frontiers Lecture Award, 1996

University of Southern California, School of Pharmacy's Outstanding Alumnus, 1993

American College of Clinical Pharmacy, Russell R. Miller Award for sustained and outstanding contribution to the literature of clinical pharmacy, 1987

American Society of Hospital Pharmacists Research and Education Foundation Award for an Outstanding Contribution to the Literature of Research in Hospital Pharmacy, 1981

#### **NATIONAL COMMITTEES AND APPOINTMENTS**

U.S. Food and Drug Administration, Pulmonary-Allergy Drugs Advisory Committee, 2009-2010

U.S. Food and Drug Administration, Center for Drug Evaluation and Research, Special Government Consultant, 1991-2009

NHLBI's National Asthma Education and Prevention Program, Coordinating Committee, representing the American Society of Hospital Pharmacists, 1992-2005

CDC, Expert Panel on Guidelines for Asthma Treatment by Emergency Medical Services (EMS), April 2004.

NHLBI Special Review Committee for RFA for Asthma Clinical Research Network, February 2003

U.S. Food and Drug Administration Pulmonary-Allergy Drugs Advisory Committee, 1986-1992

American Pharmaceutical Association, Task Force on Bioequivalency Guidelines, 1989

National Asthma Mortality Task Force, 1986

American Academy of Allergy, Task Force on Guidelines for Clinical Investigation of Non-Bronchodilator Antiasthmatic Drugs, 1985

United States Pharmacopeial Convention, Inc., Pulmonary Disease Advisory Committee, 1981-1985



**PROFESSIONAL AND SCIENTIFIC  
MEMBERSHIPS**

American Society of Health-System Pharmacists, 1968-present

American Academy of Allergy & Immunology, 1976-present

American College of Clinical Pharmacy, 1979-present  
Founding Member, 1979  
Fellow, 1985  
Research Affairs Committee, 1985  
Chairperson, Scientific Session, 1985 Annual Meeting  
Chairperson, Awards Committee, 1987-1988

American Thoracic Society, 1980-present

American Pharmacists Association, 1980-present

Pediatric Pharmacy Advocacy Group, 2003-present

Florida Pharmacy Association, 1981-2004

**PROFESSIONAL EXPERIENCE**

The University of Florida  
Professor of Pharmacy and Pediatrics with tenure, 1984-present  
Clinical Pharmacist, Pediatric Pulmonary Division, 1988-present  
Clinical Pharmacist, Pediatric Clinical Pharmacology/Toxicology Division,  
1980-1988  
Associate Professor of Pharmacy and Pediatrics, 1980-1984

U.S. Food and Drug Administration  
Visiting Scientist, Division of Pulmonary/Allergy Drugs, 8/93-5/94

The University of Iowa  
Associate Professor with tenure, College of Pharmacy, 1978-1980  
Clinical Pharmacist, Pediatric Allergy Clinic, 1975-1980  
Assistant Professor, College of Pharmacy, 1972-1978

University of Georgia, School of Pharmacy  
Assistant Professor of Clinical Pharmacy, 1971-1972

Memorial Hospital Medical Center of Long Beach, CA  
Clinical Pharmacist, 1969-1971

Cedars of Lebanon Hospital, Los Angeles  
Intern Pharmacist, 1967-1969

**EDITORIAL ACTIVITIES**

Reviewer, Journal of Allergy and Clinical Immunology, 1979-present

Reviewer, Chest, 1981-present

Reviewer, Journal of Pediatrics, 1981-present

Reviewer, The Medical Letter, 1981-present

Reviewer, American Journal of Respiratory and Critical Care Medicine,  
1984-present

Editorial Board, Journal of Pediatric Pharmacology and Therapeutics,  
2000-present

Reviewer, Journal of the American Medical Association, 2002-present

Reviewer, New England Journal of Medicine, 2002-present

Reviewer, Pharmacist's Letter, 2005-present

Editorial Board, Pharmacotherapy, 1981-2006

Member, Prescriber's Letter/Pharmacist's Letter Specialty Consultant  
Panel, 2005

Reviewer, American Journal of Hospital Pharmacy, 1975-1998

Editorial Advisor Board, Drug Intelligence and Clinical Pharmacy, 1975-  
1980

## **OTHER ACTIVITIES**

Emergency Medical Services Advisory Council, Alachua County, FL  
1995-present

Medical Advisory Committee, Alachua Country Fire Rescue, FL  
2000-2008

Board of Directors, Alachua County Organization for Rural Need, Inc.  
(ACORN), 2002-present

## **PATENTS**

Methacholine Disposable Inhaler, 2001  
Innovata Biomed Ltd/University of Florida  
International Patent Application No PCT/GB01/02648

Golub A, Hendeles L. Method and Composition for Treating  
Bronchospastic Airway Disease. U.S. Patent Number 4,689,213.  
August 25, 1987

**JOURNAL ARTICLES (REFEREED)**

1. Blake K, Hendeles L, Mehta R, Spencer T, Kunka RL. Fluticasone propionate systemic exposure using a metered-dose inhaler in preschool children (submitted).
2. Hendeles L. Advocating for patients through clinical research. *J Pediatr Pharmacol Ther* 2008;13:4-16.
3. Hendeles L, Sorkness CA. Anti-Immunoglobulin E therapy with omalizumab for asthma. *Ann Pharmacother* 2007;41:1397-410.
4. Borowitz D, Konstan MW, O'Rourke A, Cohen M, Hendeles L, Murray FT. Coefficients of fat and nitrogen absorption in healthy subjects and individuals with cystic fibrosis. *J Pediatr Pharmacol Ther* 2007;12:47-52.
5. Hatton RC, Winterstein AG, McKelvey RP, Shuster J, Hendeles L. Efficacy and safety of oral phenylephrine: systematic review and meta-analysis. *Ann Pharmacother* 2007;41:381-90.
6. Hendeles L, Colice GL, Meyer RJ. Withdrawal of albuterol inhalers containing chlorofluorocarbon propellants. *N Engl J Med* 2007;356:1344-51.
7. Workgroup on EMS Management of Asthma Exacerbations. A model protocol for Emergency Medical Services management of asthma exacerbations. *Prehosp Emerg Care* 2006;10:418-29.
8. Khan Y, Tang Y, Hochhaus G, Shuster JJ, Spencer T, Chesrown S, Hendeles L. Lung bioavailability of hydrofluoroalkane fluticasone in young children when delivered by an antistatic chamber/mask. *J Pediatr* 2006;149:793-7.
9. Pearlman DS, van Adelsberg J, Philip G, Tilles SA, Busse W, Hendeles L, Loeys T, Dass SB, Reiss TF. Onset and duration of protection against exercise-induced bronchoconstriction by a single oral dose of montelukast. *Ann Allergy Asthma Immunol* 2006;97:98-104.
10. Borowitz D, Goss CH, Stevens C, Hayes D, Newman L, O'Rourke A, Konstan MW, Wagener J, Moss R, Hendeles L, Orenstein D, Ahrens R, Oermann CM, Aitken ML, Mahl TC, Young KR, Dunitz J, Murray FT. Safety and preliminary clinical activity of a novel pancreatic enzyme preparation in pancreatic insufficient cystic fibrosis patients. *Pancreas* 2006;32:258-63.
11. Hendeles L, Marshik PL, Ahrens R, Kifle Y, Shuster J. Response to nonprescription epinephrine inhaler during nocturnal asthma. *Ann Allergy Asthma Immunol* 2005;95:530-4.
12. Hendeles L, Hatton RC, Coons TJ, Carlson L. Automatic replacement of albuterol nebulizer therapy by metered-dose inhaler and valved holding chamber. *Am J Health-Syst Pharm* 2005;62:1053-61.
13. Hendeles L, Beaty R, Ahrens R, Stevens G, Harman EM. Response to inhaled albuterol during nocturnal asthma. *J Allergy Clin Immunol* 2004;113:1058-62.
14. Wubbel C, Asmus MJ, Stevens G, Chesrown SE, Hendeles L. Methacholine challenge testing

- comparison of the two American Thoracic Society-recommended methods. *Chest* 2004;125:453-8.
15. Hendeles L, Asmus M, Chesrown S. Evaluation of cytokine modulators for asthma. *Paediatr Respir Rev* 2003;4(Suppl 1):S105-S110.
  16. Hendeles L, Asmus MJ, Chesrown S. Management of exercise-induced bronchospasm. *J Pediatr Pharmacol Ther* 2003;8:13-21.
  17. Hendeles L. Selecting a systemic corticosteroid for acute asthma in young children. *J Pediatr* 2003;142(2 Suppl):40S-44S.
  18. Hendeles L, Sherman J. Are inhaled corticosteroids effective for acute exacerbations of asthma in children? *J Pediatr* 2003;142(2 Suppl):26S-33S.
  19. Liang J, Asmus MJ, Hochhaus G, Chesrown S, Hendeles L. Differences in inhaled fluticasone bioavailability between holding chambers in children with asthma. *Pharmacotherapy* 2002;22:947-53.
  20. Asmus MJ, Vaughan LM, Hill MR, Chesrown SE, Hendeles L. Stability of frozen methacholine solutions in unit-dose syringes for bronchoprovocation. *Chest* 2002;121:1634-7.
  21. Lilly CM, Churg A, Lazarovich M, Pauwels R, Hendeles L, Rosenwasser LJ, Ledford D, Wechsler ME. Asthma therapies and Churg-Strauss Syndrome. *J Allergy Clin Immunol* 2002;109:S1-20.
  22. Twiss MA, Harman E, Chesrown S, Hendeles L. Efficacy of calcium channel blockers as maintenance therapy for asthma. *Br J Clin Pharmacol* 2002;53:243-9
  23. Julius SM, Sherman JM, Hendeles L. Accuracy of three electronic monitors for meter dose inhalers. *Chest* 2002;121:871-6.
  24. Faro A, DeNicola L, Beierle E, Langham MR, Kissoon N, Pham N, Hendeles L, Kays D, Chen M. Extracorporeal membrane oxygenation rescue therapy in a child with status asthmaticus: limits of conventional therapy. *J Pediatr Pharmacol Ther* 2001;6:504-8.
  25. Sherman J, Patel P, Hutson A, Chesrown S, Hendeles L. Adherence to oral montelukast and inhaled fluticasone in children with persistent asthma. *Pharmacotherapy* 2001;21:1464-7.
  26. Bessmertny O, Liang J, Hochhaus G, Chesrown S, Hendeles L. Fluticasone plasma concentrations in children with asthma after delivery by MDI. *J Pediatr Pharmacol Ther* 2001;6:212-7.
  27. Hendeles L, Asmus M, Chesrown S. What is the role of budesonide inhalation suspension for nebulization? *J Pediatr Pharmacol Ther* 2001;6:162-6.
  28. Sherman JM, Baumstein S, Hendeles L. Intervention strategies for children poorly adherent with asthma medications; one center's experience. *Clin Pediatr* 2001;40:253-8.

29. Asmus MJ, Barros MD, Liang J, Chesrown SE, Hendeles L. Pulmonary function response to EDTA, an additive in nebulized bronchodilators. *J Allergy Clin Immunol* 2001;107:68-72.
30. Sherman J, Hutson A, Baumstein S, Hendeles L. Telephoning the patient's pharmacy to assess adherence with asthma medications by measuring refill rate for prescriptions. *J Pediatr* 2000;136:532-6.
31. Asmus M, Hendeles L. Levalbuterol nebulizer solution: is it worth five times the cost of albuterol? *Pharmacotherapy* 2000;20:123-9.
32. Hendeles L, Davison D, Harman E, Sherman JM. The effect of cys LT1 receptor blockade on airway responses to allergen. *Pharmacotherapy* 1999;19:1243-51.
33. Asmus MJ, Sherman J, Hendeles L. Bronchoconstrictor additives in bronchodilator solutions. *J Allergy Clin Immunol* 1999;104:S53-60.
34. Ahrens RC, Hendeles L, Clarke WR, Dockhorn RJ, Hill MR, Vaughan LM, Lux C, Han S-H. Therapeutic equivalence of Spiros dry powder inhaler and Ventolin metered dose inhaler: a bioassay using methacholine. *Am J Resp Crit Care Med* 1999;160:1238-43.
35. Sherman JM, Hendeles L. Improving adherence to asthma medications. *Contemp Pediatr* 1999;16:51-64.
36. Pizzichini E, Leff JA, Reiss TF, Hendeles L, Boulet L-P, Wei LX, Efthimiadis A, Zhang J, Hargreave FE. Montelukast reduces airway eosinophilic inflammation in asthma: a randomized controlled trial. *Eur Respir J* 1999;14:12-8.
37. Marshik P, Moghaddam S, Tebbett I, Hendeles L. Degradation of histamine solutions used for bronchoprovocation. *Chest* 1999;115:194-9.
38. Leff JA, Busse WW, Pearlman D, Bronsky ED, Kemp J, Hendeles L, Dockhorn R, Kundu S, Zhang J, Seidenberg BC, Reiss TF. Montelukast, a leukotriene-receptor antagonist, for the treatment of mild asthma and exercise-induced bronchoconstriction. *N Engl J Med* 1998;339:147-52.
39. Beasley R, Fishwick D, Miles J, Hendeles L. Preservatives in nebulizer solutions: risks without benefit. *Pharmacotherapy* 1998;18:130-139.
40. Foster M, Kottler WF, Hendeles L. Relative antihistaminic potency of doxepin and hydroxyzine. *J Clin Derm* 1998;1:7-10.
41. Asmus MJ, Weinberger M W, Milavetz G, Marshik P, Teresi M E, Hendeles L. Apparent decrease in population clearance of theophylline: implications for dosage. *Clin Pharmacol Ther* 1997;62:483-89.
42. Reiss TF, Hill JB, Harman E, Zhang J, Tanaka WK, Bronsky E, Guerreiro D, Hendeles L. Increased urinary excretion of LTE4 after exercise and attenuation of exercise-induced bronchospasm by montelukast, a cysteinyl leukotriene receptor antagonist. *Thorax* 1997;52:1030-5.

43. Brueckner JW , Marshik P, Sherman J, Hendeles L. Reliability of the Medtrac MDI Chronolog; J Allergy Clin Immunol 1997;100:488-91.
44. Hendeles L, Harman E. Use of allergen bronchoprovocation to screen drugs for anti-asthma activity. Pharmacotherapy 1997;17:39S-49S.
45. Weinberger M, Hendeles L. Theophylline in asthma. N Engl J Med 1996;334:1380-88.
46. National Asthma Education and Prevention Program. Role of the pharmacist in improving asthma care. Am J Health-Syst Pharm 1995;52:1411-16.
47. Hendeles L, Jenkins J, Temple R. Revised FDA labeling guideline for theophylline oral dosage forms. Pharmacotherapy 1995;15:409-27.
48. Hendeles L, Breton AL, Beaty R, Harman E. Therapeutic equivalence of a generic slow-release theophylline tablet. Pharmacotherapy 1995;15:26-35.
49. Hendeles L, Harman E, Huang D, O'Brien R, Blake K, Delafuente J. Theophylline attenuation of airway responses to allergen; comparison with cromolyn MDI. J Allergy Clin Immunol 1995;95:505-14.
50. Kanthawatana S, Ahrens RC, McCubbin M, Bronsky E, Blake K, Hendeles L. Bioequivalence of a generic slow-release theophylline tablet in children. J Pediatr 1994;125:987-91.
51. Kraisinger M, Hochhaus G, Stecenko A, Bowser E, Hendeles L. Clinical pharmacology of pancreatic enzymes in patients with cystic fibrosis and in vitro performance of microencapsulated formulations. J Clin Pharmacol 1994;34:158-66.
52. Hendeles L. Selecting a decongestant. Pharmacotherapy 1993;13:129S-34S.
53. Hochhaus G, Hendeles L, Harman E, Moellmann H. PK/PD analysis of albuterol action: application to a comparative assessment of Beta-adrenergic drugs. Eur J Pharm Sci 1993;1:73-80.
54. Huang D, O'Brien R, Harman E, Aull L, Reents S, Visser J, Shieh G, Hendeles L. Does aminophylline benefit adults admitted to the hospital for an acute exacerbation of asthma? Ann Intern Med 1993;119:1155-60.
55. Hendeles L. Efficacy and safety of antihistamines and expectorants in non prescription cough and cold preparations. Pharmacotherapy 1993;13:154-8.
56. Carter E, Cruz M, Chesrown S, Shieh G, Reilly K, Hendeles L. Efficacy of intravenously administered theophylline in children hospitalized with severe asthma. J Pediatr 1993;122:470-6.
57. Hendeles L, Hochhaus G, Kazerounian S. Generic and alternative brand-name pharmaceutical equivalents: Select with caution. Am J Hosp Pharm 1993;50:323-9.

58. Idris AH, McDermott MF, Raucci JC, Morrabel A, McGorray S, Hendeles L. Emergency department treatment of severe asthma: metered-dose inhaler plus holding chamber is equivalent in effectiveness to nebulizer. *Chest* 1993;103:665-72.
59. Hoppe M, Harman E, Hendeles L. The effect of inhaled gallopamil, a potent calcium channel blocker, on the late-phase response in subjects with allergic asthma. *J Allergy Clin Immunol* 1992;89:688-95.
60. Hendeles L, Weinberger M, Szeffler S, Ellis E. Safety and efficacy of theophylline in children with asthma. *J Pediatr* 1992;120:177-83.
61. Blake KV, Hoppe M, Harman E, Hendeles L. Relative amount of albuterol delivered to lung receptors from a metered-dose inhaler and nebulizer solution; bioassay by histamine bronchoprovocation. *Chest* 1992;101:309-15.
62. Blake KV, Harman E, Hendeles L. Evaluation of a generic albuterol metered-dose inhaler: importance of priming the MDI. *Ann Allergy* 1992;68:169-74.
63. Harman E, Hill M, Pieper JA, Hendeles L. Inhaled verapamil-induced bronchoconstriction in mild asthma. *Chest* 1991;100:17-22.
64. Hendeles L, Dorf A, Stecenko A, Weinberger M. Treatment failure after substitution of generic pancrelipase capsules; correlation with in vitro lipase activity. *JAMA* 1990;263:2459-61.
65. Milov DE, Hill M, Andres JM, Cynamon HA, Hendeles L. Measurement of plasma prednisolone level to evaluate a prednisone treatment failure in an adolescent with Crohn's disease. *J Pediatr Gastroenterol Nutr* 1989;8:404-07.
66. Christopher MA, Harman E, Hendeles L. Clinical relevance of the interaction of theophylline with diltiazem or nifedipine. *Chest* 1989;95:309-13.
67. Blake KV, Massey KL, Hendeles L, Nickerson D, Neims A. Relative efficacy of phenytoin and phenobarbital for the prevention of theophylline-induced seizures in mice. *Ann Emerg Med* 1988;17:1024-28.
68. Christopher MA, Wyzan D, Harman E, Hendeles L. The effects of nalmefene, a potent oral opiate antagonist, on exercise-induced bronchospasm. *J Allergy Clin Immunol* 1988;82:1037-41.
69. Mac Millan M, Petty W, Hendeles L. Effect of irrigation and tourniquet application on aminoglycoside antibiotic concentrations in bone. *J Orthop Res* 1988;6:311-6.
70. Massey KL, Harman E, Hendeles L. Duration of effect of gallopamil, a calcium channel blocker, on methacholine-induced bronchoconstriction. *Pharmacotherapy* 1988;8:189-92.
71. Massey KL, Harman E, Hendeles L. Duration of protection of calcium channel blockers against exercise-induced bronchospasm: comparison of oral diltiazem and inhaled gallopamil. *Eur J Clin Pharmacol* 1988;34:555-9.

72. Hill M, Hendeles L. Evaluation of an office method of measuring theophylline serum concentrations. *J Allergy Clin Immunol* 1988;82:30-4.
73. Hendeles L, Edwards C. Clinical assessment of an enzyme immunoassay (EMIT) for measurement of serum salicylate. *J Clin Pharm Ther* 1988;13:131-8.
74. Massey KL, Hill M, Harman E, Rutledge DR, Ahrens R, Hendeles L. Dose response of inhaled gallopamil (D600), a calcium channel blocker, in attenuating airway reactivity to methacholine and exercise. *J Allergy Clin Immunol* 1988;81:912-8.
75. Blake KV, Bailey D, Zientek GM, Hendeles L. Death of a child associated with multiple overdoses of acetaminophen. *Clin Pharm* 1988;7:391-7.
76. Hendeles L, Hill M, Harman E, Moore P, Pieper J. Dose-response of inhaled diltiazem on airway reactivity to methacholine and exercise in subjects with mild asthma. *Clin Pharmacol Ther* 1988;43:387-92.
77. Sallent J, Hill M, Stecenko A, McKenzie M, Hendeles L. Bioavailability of a slow-release theophylline capsule given twice daily to preschool children with chronic asthma: comparison with liquid theophylline. *Pediatrics* 1988;81:116-20.
78. Harman E, Hill M, Fiebelman R, Pieper J, Hendeles L. The effect of oral diltiazem on airway reactivity to methacholine and exercise in subjects with mild intermittent asthma. *Am Rev Resp Dis* 1987;136:1179-82.
79. Massey KL, Hendeles L. Calcium antagonists in the management of asthma: breakthrough or ballyhoo? *Drug Intell Clin Pharm* 1987;21:505-9.
80. Hendeles L, Iafrate RP, Stillwell PC, Mangos JA. Individualizing gentamicin dosage in patients with cystic fibrosis: limitations to the pharmacokinetic approach. *J Pediatr* 1987;110:303-10.
81. Weinberger M, Hendeles L. Therapeutic effect and dosing strategies for theophylline in the treatment of chronic asthma. *J Allergy Clin Immunol* 1986;78:762-8.
82. Hendeles L, Weinberger M. Selection of a slow-release theophylline product. *J Allergy Clin Immunol* 1986;78:743-51.
83. Hill MR, Gotz VP, Harman E, McLeod I, Hendeles L. Evaluation of the asthmogenicity of propafenone, a new antiarrhythmic drug; comparison of spirometry with methacholine challenge. *Chest* 1986;90:698-702.
84. Massey KL, Hendeles L, Neims A. Identification of children for whom routine monitoring of aminoglycoside serum concentrations is not cost effective. *J Pediatr* 1986;109:897-901.
85. Milavetz G, Vaughan LM, Weinberger MM, Hendeles L. Evaluation of a scheme for establishing and maintaining dosage of theophylline in ambulatory patients with chronic asthma. *J Pediatr* 1986;109:351-4.

86. Iafate RP, Massey KL, Hendeles L. Current concepts in clinical therapeutics: asthma. *Clin Pharm* 1986;5:206-27.
87. Hendeles L, Massanari M, Weinberger M. Update on the pharmacodynamics and pharmacokinetics of theophylline. *Chest* 1985;88(suppl):103S-11S.
88. Weinberger M, Hendeles L. Theophylline use: an overview. *J Allergy Clin Immunol* 1985;76(suppl):277-84.
89. Hendeles L, Weinberger M. Theophylline product and dosing interval selection for chronic asthma. *J Allergy Clin Immunol* 1985;76(suppl):285-91.
90. Hendeles L, Weinberger M, Milavetz G, Hill M, Vaughan L. Food-induced "dose-dumping" from a once-a-day theophylline product as a cause of theophylline toxicity. *Chest* 1985;87:758-65.
91. Hendeles L, Hill M, Iafate RP. Measurement of tobramycin concentrations in saliva. *Drug Intell Clin Pharm* 1985;19:378-80.
92. Karnes HT, Iafate RP, Gudat JC, Hendeles L. Evaluation of a rapid immunoassay for monitoring serum pentobarbital concentrations. *Am J Hosp Pharm* 1984;41:2642-6.
93. Spehar AM, Hill MR, Mayhew IG, Hendeles L. Preliminary study on the pharmacokinetics of phenobarbital in the neonatal foal. *Equine Vet J* 1984;16:368-71.
94. Hendeles L, Weinberger M. Non-prescription sale of inhaled metaproterenol: déjà vu. *N Engl J Med* 1984;310:207-8.
95. Hendeles L, Iafate RP, Weinberger M. A clinical and pharmacokinetic basis for the selection and use of slow release theophylline products. *Clin Pharmacokinet* 1984;9:95-135.
96. Quattrocchi F, Karnes HT, Robinson JD, Hendeles L. Effect of serum separator blood collection tubes on drug concentrations. *Ther Drug Monit* 1983;5:359-62.
97. Weinberger M, Hendeles L. Slow-release theophylline rationale and basis for product selection. *N Engl J Med* 1983;308:760-4.
98. Hendeles L, Weinberger M. Theophylline: "A state of the art" review. *Pharmacotherapy* 1983;3:2-44.
99. Hittel WP, Iafate RP, Karnes HT, Hendeles L. Stability of pentobarbital sodium in 5% dextrose injection and 0.9% sodium chloride injection. *Am J Hosp Pharm* 1983;40:294-6.
100. Whelan HT, Hendeles L, Haberkern CM, Neims AH. High intravenous phenytoin dosage requirement in a newborn infant. *Neurology* 1983;33:106-8.
101. Iafate RP, Hendeles L, Karnes HT. Measurement of low tobramycin concentrations by the EMIT assay. *Am J Hosp Pharm* 1982;39:1965-6.

102. Hendeles L, Weinberger M. Improved efficacy and safety of theophylline for control of airways hyperreactivity. *Ann Allergy* 1982;49:247-56.
103. Prince RA, Wing DS, Weinberger M, Hendeles LS, Riegelman S. Effect of erythromycin on theophylline kinetics. *J Allergy Clin Immunol* 1981;68:427-31.
104. Weinberger M, Hendeles L, Wong L, Vaughan L. Relationship of formulation and dosing interval to fluctuation of serum theophylline concentration in children with chronic asthma. *J Pediatr* 1981;99:145-52.
105. Wong L, Hendeles L, Weinberger M. Pharmacologic prophylaxis of allergic rhinitis: relative efficacy of hydroxyzine and chlorpheniramine. *J Allergy Clin Immunol* 1981;67:223-8.
106. Hendeles L, Vaughan L, Weinberger M, Smith G. Influence of gender on theophylline dosage requirements in children with chronic asthma. *Drug Intell Clin Pharm* 1981;15:338-40.
107. Nassif EG, Weinberger MM, Shannon D, Guiang SF, Hendeles L, Jimenez D, Ekwo E. Theophylline disposition in infancy. *J Pediatr* 1981;98:158-61.
108. Bonham A, Hendeles L, Vaughan L, Weinberger M. The reliability of serum theophylline determinations from clinical laboratories. *Am Rev Res Dis* 1980;122:829-32.
109. Sarrazin E, Hendeles L, Weinberger M, Muir K, and Riegelman S. Dose-dependent kinetics for theophylline: Observations among ambulatory asthmatic children. *J Pediatr* 1980;97:825-8.
110. Hendeles L, Weinberger M. Avoidance of adverse effects during chronic therapy with theophylline. *Eur J Res Dis* 1980(suppl 109);61:103-19.
111. Weinberger M, Hendeles L. Experience with theophylline for the management of chronic asthma. *Eur J Respir Dis* 1980(suppl 109);61:120-33.
112. Hendeles L, Weinberger M, Wong L. Medical management of non-infectious rhinitis. *Am J Hosp Pharm* 1980;37:1496-504.
113. Walker J, Hendeles L. The interaction of erythromycin and theophylline in the asthmatic dental patient. *JADA* 1979;99:995-6.
114. Schaaf L, Hendeles L, Weinberger M. Suppression of seasonal allergic rhinitis symptoms with daily hydroxyzine. *J Allergy Clin Immunol* 1979;63:129-33.
115. Sintek C, Hendeles L, Weinberger M. Inhibition of theophylline absorption by activated charcoal. *J Pediatr* 1979;94:314-6.
116. Weinberger M, Hendeles L, Bighley L. The relation of product formulation to absorption of oral theophylline. *N Engl J Med* 1978;299:852-7.
117. Hendeles L, Weinberger M, Wyatt A. Guide to oral theophylline therapy for the treatment of

- chronic asthma. *Am J Dis Child* 1978;132:876-80.
118. Hendeles L, Weinberger M, Johnson G. Monitoring serum theophylline levels. *Clin Pharmacokinet* 1978;3:294-312.
  119. Hendeles L, Weinberger M, Bighley L. Disposition of theophylline after a single intravenous infusion of aminophylline. *Am Rev Resp Dis* 1978;118:97-103.
  120. Ekwo E, Hendeles L, Weinberger M. Those who make decisions about management of children with asthma: pharmacist-physician interaction. *Am J Hosp Pharm* 1978;35:295-9.
  121. Sintek C, Hendeles L, Weinberger M. Activated charcoal adsorption of theophylline in-vitro. *Drug Intell Clin Pharm* 1978;12:158-9.
  122. Wyatt R, Weinberger M, Hendeles L. Oral theophylline dosage for the management of chronic asthma. *J Pediatr* 1978;92:125-30.
  123. Hendeles L, Kagan BM. The prevention of meningococcal disease in the community. *Drug Intell Clin Pharm* 1978;12:278-3.
  124. Hendeles L, Burkey S, Bighley L, Richardson R. Unpredictability of theophylline saliva measurements in chronic obstructive pulmonary disease. *J Allergy Clin Immunol* 1977;60:335-8.
  125. Alexander MR, Hendeles L, Guernsey B. The beta-2 agonist bronchodilators. *Drug Intell Clin Pharm* 1977;11:526-32.
  126. Matheson LE, Bighley L, Hendeles L. Drug interference with the Schack and Waxler plasma theophylline assay. *Am J Hosp Pharm* 1977;34:496-9.
  127. Hendeles L, Weinberger M, Bighley L. Absolute bioavailability of oral theophylline. *Am J Hosp Pharm* 1977;34:252-7.\*
  128. Weinberger M, Hendeles L. Management of asthma. *Postgrad Med* 1977;61:85-103.
  129. Hendeles L, Bighley L, Richardson RH, Hepler CD, Carmichael J. Frequent toxicity from IV aminophylline infusions in critically ill patients. *Drug Intell Clin Pharm* 1977;11:12-18. (published again as a historical view — *Ann Pharmacother* 2006;40:1417-23).
  130. Weinberger M, Hendeles L. Pharmacotherapy of asthma. *Am J Hosp Pharm* 1976;33:1071-80.
  131. Hendeles L. A need for counter-detailing antibiotics. *Am J Hosp Pharm* 1976;33:918-24.
  132. Hanson D, Hendeles L. Guide to total dose intravenous iron dextran therapy. *Am J Hosp Pharm* 1974;31:592-5.
  133. Hendeles L. Uncomplicated gonococcal infections. *Drug Intell Clin Pharm* 1973;7:205-7.

134. Hendeles L. A guide to gentamicin therapy. *Drug Intell Clin Pharm* 1971;5:393-96.

\* The most frequently cited article from AJHP for the years 1955-1986 (*Am J Hosp Pharm* 1989;46:126-28).

#### **REFEREED RESEARCH LETTERS**

1. Hendeles L, Khan YR, Shuster JJ, Spencer T. Comparison of 2 dosimeters by methacholine challenge. *J Allergy Clin Immunol* 2007;120:1218-9.
2. Khan YR, McDonough P, Cockcroft DW, Davis BE, Hendeles L. Nebulizer output for methacholine challenges with the KoKo Digidoser. *J Allergy Clin Immunol* 2005;116:924-6.

#### **EDITORIALS AND COMMENTARIES**

1. Hendeles L. Fifty years ago in *The Journal of Pediatrics* -- Aminophylline (theophylline ethylenediamine) poisoning in children. *J Pediatr* 2006;149:361.
2. Hendeles L, Altenburger KM, Benton T. Self-administration at school of prescribed medications for asthma and anaphylaxis. *J Pediatr Pharmacol Ther* 2003;8:250-1.
3. Hendeles L, Segal R. Pharmacoeconomic studies of asthma controller drugs: marketing gimmick or icing on the cake? *Pharmacother* 2002;22:131-3.
4. Hendeles L, Marshik P. Zafirlukast for chronic asthma: safe, convenient but is it effective? *Ann Pharmacother* 1997;31:1084-86.
5. Hendeles L. Cetirizine: A new antihistamine with minimal sedation. *Pharmacotherapy* 1996;16:967-68.
6. Hendeles L, Marshik P. Zileuton: A new therapy for asthma or just the first of a new class of drugs? *Ann Pharmacother* 1996;30:873-75.
7. Weinberger MW, Hendeles L. Reassessing the therapeutic range for theophylline: Another perspective. *Pharmacotherapy* 1993;13:598-01.
8. Hendeles L, Harman E. Should we abandon the notion that calcium channel blockers are potentially useful for asthma? *J Allergy Clin Immunol* 1987;79:853-56.
9. Hendeles L, Weinberger M. Combined use of theophylline and beta-2 agonists. *Immunol Allergy Pract* 1983;5:300-04.
10. Hendeles L. Adjusting theophylline dosage for smokers. *J Resp Dis* 1983;4:73-74.
11. Hendeles L, Weinberger M. A time to abandon the use of iodides in pulmonary diseases. *J Allergy Clin Immunol* 1980;66:177-78.

12. Hendeles L, Weinberger M. Poisoning patients with intravenous theophylline. *Am J Hosp Pharm* 1980;37:49-50.
13. Weinberger M, Hendeles L. Role of dialysis in the management and prevention of theophylline toxicity. *Dev Pharmacol Ther* 1980;1:26-30.
14. Kagan B, Hendeles L. Meningococcal prophylaxis in 1977. *Infectious Diseases* 1977;7:4.
15. Hendeles L, Weinberger M. Dyphylline - the "untheophylline" xanthine bronchodilator. *Drug Intell Clin Pharm* 1977;11:424.
16. Hendeles L. Wandering from bed to bed. *Drug Intell Clin Pharm* 1975;9:270-271.

#### **EDITOR FOR JOURNAL SUPPLEMENTS**

1. Hendeles L (Guest Editor) and Scheife RT (Editor). New Frontiers in asthma therapy: Leukotriene receptor antagonists and 5-lipoxygenase inhibitors. *Pharmacotherapy* 1997;12:1S-54S.
2. Hendeles L (Guest Editor) and Scheife RT (Editor). Clinical use of decongestants. *Pharmacotherapy* 1993;13:1015-465.

#### **OTHER ARTICLES (NON-REFEREED JOURNALS)**

1. Hendeles L. Can pharmacist-compounded tobramycin be substituted for TOBI? University of Florida Pediatric Pulmonary Cystic Fibrosis Newsletter. Summer, 2005.
2. Carroll RC, Hendeles L. Pancreatic enzyme supplementation in cystic fibrosis patients. *U.S. Pharmacist*, January 2002;27:HS 34, 37-38, 42-43.
3. Sherman J, Hendeles L. Practical pharmacotherapy for pediatric asthma. *Pediatr Ann* 2000;29:768-73.
4. Hendeles L. Dose selection and dosing interval determination for LTRA use in asthma. *Postgrad Med*, September 2000(special issue):12-21.
5. Hendeles L. Montelukast for persistent asthma. *Florida Pharmacy Today*, 1999;63:12-4 and 30.
6. Hendeles L. Bronchoconstrictors may damage lung function when administered repetitively. *Board of Pharmacy Newsletter*, Florida Department of Health 1998;1:6.
7. Anonymous. Drugs for ambulatory asthma. *Medical Letter* 1991;33:9-12.
8. Hendeles L, Weinberger M. Theophylline - a model for therapeutic drug monitoring. *Proceedings of the 1st Pan Pacific - Asian Congress of Clinical Pharmacy*. Penang, Malaysia November 1990.
9. Knudsen AK, Hendeles L, Williams RB. Selecting generic drugs and generic drug vendors: a

- guide for Florida pharmacists. J Fla Pharm Assoc 1990;54:10-13.
10. Hendeles L. Switch Candidates from the Pulmonary Perspective. Drug Information 1990;24:83-89.
  11. Hendeles L. Slow-release theophylline: Do not substitute. Am Pharm 1989;182:22-24.
  12. Hendeles L, Weinberger M. Pharmacokinetic basis for the selection of a slow-release theophylline product. Proceedings from the International Colloquium of Progress in Pulmonary Medicine in Cannes, France, Pracon, Inc., Reston VA, October, 1988.
  13. Hoppe MM, Iafrate RP, Hendeles L, Neims A. A pediatric drug dosing and monitoring guide. Fl J Hosp Pharm 1988;8:259-69.
  14. Hendeles L. Asthma therapy: state of the art, 1988. J Respir Dis 1988;3:82-08.
  15. Anonymous. Drugs for Asthma. The Medical Letter 1987;29:11-16.
  16. Hendeles L, Weinberger M. Slow-release theophylline for the management of chronic asthma. Singapore Med J 1985;26:83-90.
  17. Hendeles L, Weinberger M. Measurement of theophylline serum concentrations in the physician's office. Immunol Allergy Pract 1984;6:104-10.
  18. Hendeles L. OTC metaproterenol. Fla Pharm J 1983;47:4-6.
  19. Weinberger M, Hendeles L. How to keep serum levels in the therapeutic range: practical guide to using theophylline. J Resp Dis 1981;2:12-27.
  20. Weinberger M, Hendeles L. Formulation and dosage requirements for theophylline in the treatment of asthma. Curr Med Res Opin 1979(suppl 6):6:116-130.
  21. Hendeles L, Weinberger M. The interaction of theophylline and erythromycin. US Pharmacist 1978;3:10-11.
  22. Hendeles L. Drug therapy of allergic rhinitis. Iowa Pharmacist 1977;32:10-11.

#### **ELECTRONIC MEDIA**

1. Hendeles L and Weinberger M. Theophylline Use in Asthma. In: UpToDate, Rose, BD (Ed), UpToDate, Waltham, MA, November, 2008 (CD Rom).
2. Hendeles L, Weinberger M. Pharmacotherapy of Asthma: A Primer for Pharmacists. Glaxo Wellcome Trends in Pharmacy April 1997 (on Website): [www.helix.com/member/news/trends\\_pharm/April\\_97/April97\\_ce.htar](http://www.helix.com/member/news/trends_pharm/April_97/April97_ce.htar).

#### **BOOKS**

1. Merkus FWHM, Hendeles L (eds): Sustained-Release Theophylline: A Biopharmaceutical Challenge to a Clinical Need. Amsterdam, Excerpta Medica, 1983.

## **BOOK CHAPTERS AND MONOGRAPHS**

1. Kelly HW and Hendeles L. Bronchodilators. Chapter in M Light (Ed), Bluebook, American Academy of Pediatrics, 2009 (in press).
2. Hendeles L, Schatz M. Ambulatory Management of Asthma During Pregnancy, in Briggs G, Nageotte M (eds). Diseases, Complications, and Drug Therapy in Obstetrics: A Guide for Clinicians. Bethesda, MD. American Society of Health-System Pharmacists, 2009 (in press).
3. Hayden ML, Hendeles L, Ortiz G. Improving the Outcomes of Allergic Rhinitis Treatment: Monograph #2, Pragmaton Office of Medical Education, 2001.
4. Hayden ML, Hendeles L, Ortiz G. Diagnostic Challenges in Allergic Rhinitis: Monograph #1, Pragmaton Office of Medical Education, 2001.
5. Weinberger M, Hendeles L. Theophylline and Phosphodiesterase Inhibitors, in Middleton E, Reed CE, Ellis EF, Adkinson NF, Yunginger JW. (eds), Allergy: Principles and Practice, ed 5. St. Louis, CV Mosby, 1998, pp 589-611.
6. Weinberger M, Hendeles L. Theophylline, in Middleton E, Reed CE, Ellis EF, Adkinson NF, Yunginger JW, Busse WW (eds), Allergy: Principles and Practice, ed 4. St. Louis, CV Mosby, 1993, pp 816-855.
7. Iafrate RP, Hendeles L. Asthma, in Herfindal ET, Gourley DR, Hart LL (eds), Clinical Pharmacy and Therapeutics, ed 4. Baltimore, Williams & Wilkins, 1988, pp 354-373.
8. Hendeles L, Massanari M, Weinberger M. Theophylline, in Middleton E, Reed CE, Ellis EF, Adkinson NF, Yunginger JW (eds), Allergy: Principles and Practice, ed 3. St. Louis, CV Mosby, 1988, pp 673-714.
9. Weinberger M, Hendeles L. in Bierman CW, Pearlman DS (eds), Allergic Diseases from Infancy to Adulthood, ed 2. Philadelphia, WB Saunders, 1988, pp 253-278.
10. Ellis E, Hendeles L. in Taylor WJ, Cavaness MHD (eds), A Textbook for the Clinical Applications of Therapeutic Drug Monitoring, Abbott Laboratories, Diagnostics Division, Irving, TX, 1986, pp 185-201.
11. Hendeles L, Massanari MJ, Weinberger M. Theophylline, in Evans WE, Schentag JJ, Jusko WJ (eds), Applied Pharmacokinetics, ed 2. San Francisco, Applied Therapeutics Inc. 1986, pp 1105-1188.
12. Hendeles L, Weinberger M. Slow-release oral bronchodilators for prophylactic therapy of chronic asthma, in Prescott LF, Nimmo WS (eds) Rate Control in Drug Therapy. Edinburgh, Scotland, Churchill Livingstone, 1985, pp 254-264.
13. Weinberger M, Hendeles L. Methylxanthines, in Weiss EB, Segal MS, Stein MS (eds), Bronchial Asthma: Mechanisms and Therapeutics. Boston, Little, Brown & Co, 1985, pp 646-

- 674.
14. Weinberger M, Hendeles L. Use of theophylline for asthma, in Clark TJH, Godfrey S (eds), *Asthma*. London, Chapman and Hill, 1984, pp 336-358.
  15. Weinberger M, Hendeles L. Theophylline for chronic asthma: rationale for treatment, product selection and dosage schedule, in Jonkman JHG, Jenne JW, Simons FER (eds), *Sustained Release Theophylline in the Treatment of CRAO*. Amsterdam, Excerpta Medica, 1984, pp 131-142.
  16. Hendeles L, Weinberger M. Measurement of theophylline serum concentrations in the physician's office, in Jonkman JHG, Jenne JW, Simons FER (eds), *Sustained Release Theophylline in the Treatment of CRAO*. Amsterdam, Excerpta Medica, 1984, pp 41-48.
  17. Weinberger M, Hendeles L. The importance of the absorption characteristics of theophylline in clinical practice, in Merkus FWHM, Hendeles L (eds), *Sustained-Release Theophylline: A Biopharmaceutical Challenge to a Clinical Need*. Amsterdam, Excerpta Medica, 1983, pp 155-168.
  18. Hendeles L, Weinberger M. Methods of determining bioavailability of slow-release theophylline products, in Merkus FWHM, Hendeles L (eds), *Sustained Release Theophylline: A Biopharmaceutical Challenge to a Clinical Need*. Amsterdam, Excerpta Medica, 1983, pp 118-135.
  19. Weinberger M, Hendeles L. Theophylline, in Petty T (ed), *Recent Advances in Respiratory Medicine - 3*, Edinburgh, Scotland, Churchill Livingstone, 1983, pp 63-77.
  20. Hendeles L, Weinberger M. Theophylline, in Middleton E, Ellis E, Reed C (eds), *Allergy: Principles and Practice*, ed 2. St. Louis, CV Mosby, 1983, pp 535-574.
  21. Weinberger M, Hendeles L. Asthma in childhood, in Conn HF (ed), *Current Therapy*. Philadelphia, WB Saunders, 1982, pp 589-597.
  22. Weinberger M, Hendeles L, Ahrens R. Pharmacologic management of reversible obstructive airways disease. *Med Clin N Am* 1981;65:579-613.
  23. Hendeles L, Weinberger M. Theophylline: therapeutic use and serum concentration monitoring, in Taylor WJ, Finn AL (eds), *Individualizing Drug Therapy. Practical Applications of Drug Monitoring*. New York, Gross, Townsend, Frank, 1981, pp 31-65.
  24. Weinberger M, Hendeles L, Johnson G. Rationale and procedures for measuring serum levels of theophylline, in Baer D, Dito W (eds), *Interpretation of Therapeutic Drug Monitoring*. Chicago, Am Soc Clin Pathologists, 1981, pp 98-137.
  25. Weinberger M, Hendeles L, Ahrens R. Clinical pharmacology of drugs used for asthma. *Pediatr Clin N Am* 1981;28:47-75.
  26. Ahrens R, Hendeles L, Weinberger M. Clinical pharmacology of drugs used in the treatment of

- asthma, in Yaffe SJ (ed), *Pediatric Pharmacology*. New York, Grune and Statton Inc, 1980, pp 233-280.
27. Hendeles L, Weinberger M, Johnson G. Theophylline, in Jusko W, Schentag J, Evans W (eds), *Applied Pharmacokinetics*. San Francisco, Applied Therapeutics, Inc, 1980, pp 95-138.
  28. Weinberger M, Hendeles L. Pharmacologic management of asthma rhinitis, anaphylaxis and urticaria, in Bierman CW, Pearlman DS (eds), *Allergic Diseases of Infancy, Childhood and Adolescence*. Philadelphia, WB Saunders, Philadelphia, 1980, pp 311-332.
  29. Weinberger M, Hendeles L. Asthma, in Gillis S, Kagan BM (eds), *Current Pediatric Therapy*, ed 9. Philadelphia, WB Saunders, 1980, pp 631-640.
  30. Weinberger M, Hendeles L. Pharmacotherapy of asthma, in Miller RR, Greenblatt D (eds), *Drug Therapy Reviews*, New York, Elsevier/North Holland, 1979, vol 2, pp 1-23.
  31. Weinberger M, Hendeles L. Antiasthmatic drugs, in Miller R, Greenblatt D (eds), *Handbook of Drug Therapy*. New York, Elsevier/North Holland, 1979, pp 927-951.
  32. Hendeles L, Weinberger M. Treatment of chronic obstructive lung disease, in Gerbino P (ed): *Self Assessment of Current Knowledge of Clinical Pharmacy*, ed 2. Flushing, NY, Medical Examination Publishing Co, 1978, pp 192-215.
  33. Tatro D, Hendeles L. Adverse drug reactions in children, in Gillis S, Kagan BM (eds): *Current Pediatric Therapy - 7*. Philadelphia, WB Saunders, 1975, pp 687-692.
  34. Hendeles L. Venereal diseases, in Gerbino P (ed): *Self Assessment of Current Knowledge in Clinical Pharmacy*. Flushing, NY, Medical Examination Publishing Co, 1974, pp 114-121.

#### **LETTERS TO THE EDITOR (LAST 7 YEARS)**

1. Meyer RJ, Hendeles L, Colice GL. Albuterol inhalers. *N Engl J Med* 2007;356:2749.
2. Hendeles L, Hatton RC. Oral phenylephrine: an ineffective replacement for pseudoephedrine? *J Allergy Clin Immunol* 2006;118:279-80.
3. Weinberger M, Hendeles L. Levalbuterol. *Ann Allergy Asthma Immunol* 2003;91:587-8.
4. Hendeles L, Hartzema A. Levalbuterol is not more cost-effective than albuterol for COPD. *Chest* 2003;124:1176.
5. Asmus MJ, Hendeles L, Weinberger M, Ahrens RC, Bisgaard H, Lötval J, O'Byrne PM, Cockcroft DW. Levalbuterol has not been established to have therapeutic advantage over racemic albuterol. *J Allergy Clin Immunol* 2002;110:325.
6. Asmus MJ, Hendeles L, Ahrens RC, Clarke WR, Nielsen LP, Dahl R. Therapeutic ratio of

inhaled corticosteroids: fact or fiction? *Am J Respir Crit Care Med* 2001;164:1998-9.

7. Hendeles L. Unapproved generic pancreatic enzymes. *J Pediatr Pharmacol Ther* 2001;6:10-11.

## **ABSTRACTS**

1. Hendeles L, Khan Y, Massanari M, Spencer T, Shuster J, Chesrown S. The effect of omalizumab on airway responsiveness to adenosine in asthma patients with poor adherence to inhaled steroids. Presented at the 2007 Annual Meeting of the American Thoracic Society, San Francisco, California, May, 2007.
2. Blake K, Hendeles L, Spencer T, Mehta R, Beerah M, Daley-Yates P, Kunka R. Systemic exposure following fluticasone propionate metered dose inhaler using hydrofluoroalkane propellant with valved holding chambers and face-masks in pre-school children. Presented at the 2006 Annual Meeting of the American College of Clinical Pharmacy, St. Louis, Missouri, October 29, 2006.
3. Mack CL, Zineh I, Hendeles, L. Systemic cytokine balance differs between asthma patients with and without positive response to adenosine bronchoprovocation. Presented at the 2006 Annual Meeting of the American College of Clinical Pharmacy, St. Louis, Missouri, October 27, 2006.
4. Khan YR, Hochhaus G, Spencer T, Shuster J, Hendeles L. Relative amount of fluticasone delivered by HFA-MDI to children of different ages. *J Allergy Clin Immunol* 2006;117:S91.
5. Asmus MJ, Hochhaus G, Tang Y, Spencer LT, Chesrown SE, Hendeles L. Impact of new anti-static valved-holding chamber on airway delivery of inhaled fluticasone propionate in asthmatic children. *Am J Respir Crit Care Med* 2004;169:A150.
6. Asmus MJ, Hochhaus G, Tang Y, Chesrown SE, Hendeles L. Effect of MDI valved holding chamber antistatic coating on bioavailability of inhaled fluticasone in subjects with asthma. *Am J Respir Crit Care Med* 2004;169:A313.
7. Ward M, Weitzel KW, Hendeles L, Asmus MJ, Van Riper BW. Evaluation of existing patient data from a community pharmacy-based asthma program. *J Am Pharm Assoc* 2004;44:262-3.
8. Dugan BD, Weitzel KW, Asmus MJ, Hendeles L, Buie B, Van Riper BW, Chesrown SE. Comparison of pharmacy refill history versus spirometry as an indicator of asthma control in community pharmacy practice. *J Am Pharm Assoc* 2004;44:233-4.
9. Hendeles L, Erb TA, Bird S, Hustad CM, Edelman JM. Post-exercise response to albuterol after addition of montelukast or salmeterol to inhaled fluticasone. *J Allergy Clin Immunol* 2004;113(suppl):S34.
10. Wubbel C, Asmus MJ, Chesrown SE, Hendeles L. Comparison of the two ATS-recommended methacholine challenge tests (MCT). *Am J Respir Crit Care Med* 2003;167:A635.
11. Ahrens RC, Hendeles L, Teresi ME, Lux CR, Vanden Burgt J, Hart KA, Ekholm BP. Relative potency of beclomethasone propionate (BDP), delivered by HFA-MDI, and fluticasone propionate

- (FP) delivered by diskus. *Eur Respir J* 2003;22(suppl 45):236s.
12. Asmus MJ, Liang J, Chesrown SE, Hendeles L. Efficacy of albuterol delivery by Pari LC-Star nebulizer. *J Allergy Clin Immunol* 2002;109:S242.
  13. Liang J, Asmus MJ, Hochhaus G, Chesrown SE, Hendeles L. Relative amount of inhaled fluticasone delivered to the airways of asthmatic children by two similar MDI chambers. *J Allergy Clin Immunol* 2002;109:S242.
  14. Bessmertney O, Liang J, Hochhaus G, Chesrown S, Hendeles L. Fluticasone propionate (FP) plasma concentrations in children with asthma. *Am J Respir Crit Care Med* 2001;163:A518.
  15. Patel P, Hutson A, Sherman J, Chesrown S, Hendeles L. Do children with asthma take oral montelukast more consistently than inhaled fluticasone? *Pharmacotherapy* 2000;20:1267-8.
  16. Teresi M, Wilson J, Scher H, Han S-H, Flewelling J, Sherman J, Hendeles, L, Ahrens R. Airway responsiveness to allergen and histamine as a bioassay for comparing inhaled corticosteroid preparations. *Am J Resp Crit Care Med* 1997;155:A353.

#### **SELECTED PRESENTATIONS**

1. Controversies in Asthma Therapy. New Developments in Clinical Pharmacy and Clinical Pharmacology. Stresa, Italy, June 13, 2009.
2. Poor Adherence to Asthma Medications. University of Florida Medicine Grand Rounds, Gainesville, Florida, April 2, 2009.
3. Current Controversies in Pediatric Asthma Therapy. Hadassah Medical Center Symposium on Chronic Diseases in Children. Jerusalem, Israel, December 4, 2008.
4. Management of Asthma in Pregnancy. American College of Clinical Pharmacy Annual Meeting. Louisville, Kentucky, October 20, 2008.
5. Current Controversies in Asthma Therapy. University of Florida Medicine Grand Rounds, Gainesville, Florida, September 25, 2008.
6. What is the Role of Leukotriene Antagonists in Respiratory Disease? American Academy of Allergy Asthma & Immunology Annual Meeting, San Diego, California, February, 2007.
7. Update in Asthma Management, 14th World Congress for Bronchology, Buenos Aires, Argentina, June, 2006.
8. Study Designs for Bronchodilators and ICS Pharmacokinetics, American Academy of Asthma, Allergy & Immunology Annual Meeting, Miami, FL, March, 2006.
9. ICS Pharmacokinetics: The Impact of Safety and Efficacy, American Academy of Allergy Asthma and Immunology Annual Meeting, San Antonio, TX, March, 2005.
10. Pharmaceutical Care for Asthma, Sixth Annual Kuwait Pharmaceutical Association Conference,

Kuwait, February, 2004.

11. Role of Health-System Pharmacists in Asthma, National Asthma Education and Prevention Program, Coordinating Committee Meeting, Bethesda, MD, December. 2003.
12. New CFC-Free Asthma Inhalers -- What You Need to Know and Optimizing the Delivery of Inhaled Medications, NHLBI National Conference on Asthma 2003 Grand Rounds, Washington, D.C., June, 2003.
13. Delivery of Inhaled Medications to Young Children with Asthma, Visiting Professor Lecture Series, US Food and Drug Administration (FDA), Center for Drug Evaluation and Research (CDER), Rockville, MD, October, 2002.
14. Cytokine Modulation as Novel Therapy for Asthma, International Congress of Pediatric Pulmonology, Nice, France, February, 2002.
15. Recommendations for the Pancreatic Enzymes, CF Foundation Pediatric Nutrition Consensus Conference, Bethesda, MS, March, 2001.
16. Use of Nocturnal Asthma to Evaluate Bronchodilation, FDA-Visiting Scientist Program, Rockville, MD, August, 2000.
17. Daniel Simmons Honorary Lecturer, UCLA Department of Medicine, Los Angeles, CA, September 1999.
18. Howard Q. Ferguson Pharmacotherapy Lecture Award, University of North Carolina School of Pharmacy, Chapel Hill, NC, March 1994.
19. Efficacy of Antihistamines for Cold Symptoms. Testimony before the House Subcommittee on Human Resources and Intergovernmental Relations. Conducted by Congressman Ted Weiss. Washington D.C., April 1992.
20. Merrell-Dow Lecturer in Clinical Pharmacy, University of Manchester, Manchester, England, May 1991.
21. OTC Inhaled Metaproterenol. FDA Pulmonary-Allergy Drugs Advisory Committee Meeting. Bethesda, MD, May 1983.
22. IV Aminophylline Dosing for Revised Package Insert. FDA Pulmonary-Allergy Drugs Advisory Committee. Bethesda, MD, November 1976.

## **GRANTS AND CONTRACTS**

(available upon request)

## **RESEARCH FELLOWS AND TRAINEES**

*Curriculum Vitae*  
*Leslie Hendeles*  
*Page 24*

(available upon request)